Center for Acute Care Nephrology, Division of Nephrology and Hypertension, University of Cincinnati College of Medicine, Cincinnati, OH 45229, USA.
BMC Med. 2011 Dec 21;9:135. doi: 10.1186/1741-7015-9-135.
Acute kidney injury (AKI) in hospitalized patients is independently associated with increased morbidity and mortality in pediatric and adult populations. Continued reliance on serum creatinine and urine output to diagnose AKI has resulted in our inability to provide successful therapeutic and supportive interventions to prevent and mitigate AKI and its effects. Research efforts over the last decade have focused on the discovery and validation of novel urinary biomarkers to detect AKI prior to a change in kidney function and to aid in the differential diagnosis of AKI. The aim of this article is to review the AKI biomarker literature with a focus on the context in which they should serve to add to the clinical context facing physicians caring for patients with, or at-risk for, AKI. The optimal and appropriate utilization of AKI biomarkers will only be realized by understanding their characteristics and placing reasonable expectations on their performance in the clinical arena.
在住院患者中,急性肾损伤(AKI)与儿科和成人人群的发病率和死亡率增加独立相关。持续依赖血清肌酐和尿输出量来诊断 AKI,导致我们无法提供成功的治疗和支持干预措施来预防和减轻 AKI 及其影响。过去十年的研究工作重点是发现和验证新型尿生物标志物,以便在肾功能改变之前检测 AKI,并帮助 AKI 的鉴别诊断。本文的目的是回顾 AKI 生物标志物的文献,重点关注它们应该在何种情况下有助于补充临床医生在治疗或面临 AKI 风险的患者时所面临的临床背景。只有了解 AKI 生物标志物的特点,并对其在临床领域的表现提出合理的期望,才能实现 AKI 生物标志物的最佳和适当利用。